CD38+NK:?

Huixian Chen1, Kehua Fang2, Jinbao Zong3

  • 1Center for Clinical Research, The Affiliated Hospital of Qingdao University, Qingdao 266003, China; Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.

Immunobiology
|August 20, 2025
PubMed
まとめ

多発性骨髄腫の患者では,CD38陽性自然キラー (NK) 細胞が減少し,変化し,免疫抑制性腫瘍の微環境と疾患の進行に潜在的に寄与する.